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Introduction 
The aim of this paper is to describe the processes and procedures involved in planning, conduct-
ing and reporting monitoring activities for large clinical trials of investigational medicinal prod-
ucts, with a focus on those done in resource-limited settings. Although the framework and guide-
lines underpinning these procedures will be the same regardless of setting, the approaches taken 
and the needs to be addressed may differ. Thus we aim to ensure that the guidance presented is 
relevant and applicable to all settings. 
 The paper is divided into three main sections: Rationale for monitoring clinical trials; Trial 
oversight and risk assessment procedures, including considerations for trial design; and Guidance 
for on-site monitoring. The first section provides an overview for all readers, while the second 
may be most useful for investigators when designing the trial and applying for funding. The third 
section is aimed at trial managers/monitors travelling to sites for on-site monitoring visits.  
 This guide is based on International Council for Harmonisation - Good Clinical Practice (ICH 
GCP 1996). It is intended for use as a reference text but local/international requirements should 
always be adhered to as procedures and requirements may vary across institutes and countries.  
 
Rationale for Monitoring Clinical Trials 
A number of regulations, standards and guidelines create the framework for the conduct of clini-
cal trials globally, all of which hold, at their core, the ethical principles as set out by the Declara-
tion of Helsinki (WMA 2013). Whether conducted in rich or poor settings, all trials must follow 
this same framework, though the way in which trials are implemented may differ across regions.  
 Building on the principles of the Declaration of Helsinki, ICH-GCP (1996) is the guideline on 
which all other references are based and which is considered the gold standard for clinical trials 
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globally. Monitoring is an integral part of Good Clinical Practice and ensures that a trial is being 
conducted in compliance with international regulations, standards and guidelines (ICH GCP 1996). 
 From the perspective of trial investigators, effective monitoring is paramount to the conduct 
of robust clinical trial research ensuring that: 
(a) procedures are consistent and safe for each participant throughout the trial; 
b) stringent checks on data collection and procedures provide quality data and credibility to re-
sults; and  
(c) there is sufficient oversight to help the trial reach its objectives and does not, for example, 
continue any longer than initially planned due to unforeseen issues which could have been identi-
fied during monitoring. 
 Monitoring is critical for the protection of the rights and well-being of trial participants and 
for the collection and analysis of high-quality data on which new products/indications and guide-
lines will be based. Regardless of the trial sites’ location, whether in settings with many or few re-
sources, the need for, and importance of, monitoring does not alter. 
 
Trial Oversight and Risk Assessment Procedures 
Roles and responsibilities 
There are a number of roles and responsibilities that must be considered and delegated when 
conducting clinical trials. The sponsor is responsible for ensuring that the trial is adequately moni-
tored. Monitoring may be carried out by the sponsor or delegated (ICH GCP 1996). It is recom-
mended that monitoring procedures are detailed in a Monitoring Standard Operating Procedure, 
so that staff responsibilities are clearly defined (NIHR 2012). Depending on the outcome of the 
risk assessment, this internal monitoring may be supplemented with an external audit at some 
point towards the beginning of the trial.  
 
Types of monitoring 
There are a number of ways in which a clinical trial can be monitored both off -site (through spe-
cifically appointed committees and/or central/statistical monitoring) and on-site. Types of moni-
toring are unlikely to differ for resource-limited settings, although the level of monitoring may be 
raised in various areas if the risk is deemed higher.  
 
Trial committees for oversight 
A clinical trial may be overseen by a number of committees, depending on the extent and nature 
of the trial. For example:  
 The Trial Steering Committee is generally comprised of an independent chair, at least two 
additional independent members, up to two principal investigators and a trial manager or statis-
tician as appropriate (MRC 1998). The role of the Trial Steering Committee is to provide overall 
supervision and advice, and the ultimate decision for the continuation of the trial lies with it.  
 The Data Monitoring Committee /Data Safety Monitoring Board is group of experts usually, 
but not always, independent of the management of the trial. In a blinded trial, this is the only 
committee to review unblinded clinical data. Its main duty is to monitor safety of the trial, in par-
ticular to review serious adverse events, suspected unexpected serious adverse events and mor-
tality, across the arms of the trial and overall. The Data Monitoring Committee makes recom-
mendations to the Trial Steering Committee, the chief investigator and the sponsor on continua-
tion or early stopping of the trial based on safety or ethical issues.  
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 According to guidelines, trials involving subjects with life-threatening illnesses, vulnerable 
populations and/or involving significant potential risks require a Data Monitoring Committee 
/Data Safety Monitoring Board (DAMOCLES study group 2005 and WHO 2005) and the Medical 
Research Council of the UK recommends that an element of expert advice, independent of the 
chief or principal investigator should be incorporated into the conduct of a trial (MRC 1998). The 
terms of reference for each committee can be detailed in a specific charter. The Medical Re-
search Council and WHO have created templates of such charters, which can be used as a refer-
ence (DAMOCLES study group 2005 and WHO 2005). 
 
Central monitoring  
In addition to trial oversight committees, the trial may be centrally monitored. For example, key 
data may be identified and reviewed by the central coordinating study team at periods specified 
in advance. Eligibility criteria may be reviewed monthly (or more frequently at the beginning of 
the trial); adverse events may be reviewed routinely by members of the Trial Management 
Group; consent forms may be reviewed centrally to assure the trial team of the timing of consent 
and that the forms have been completed correctly. Consent forms can only be reviewed centrally 
if a specific clause has been agreed to in the consent form, stating that the participant is aware 
that his/her data will be reviewed outside their medical centre and, if applicable, country of 
origin. The trial team may also review drug accountability logs centrally to ensure that the site 
has sufficient stock, and dosing and enrolment data. 
 Information relating to the primary endpoint may be reviewed centrally at specific time 
points and in cumulative weekly or monthly reports with data pertaining to recruitment rates, 
withdrawal and losses to follow-up. Safety reports may be submitted to the Data Monitoring 
Committee /Data Safety Monitoring Board at specified time points, e.g. 6-monthly, and statistical 
analyses could be used at regular intervals to identify unusual patterns of data, or detect devia-
tions from the protocol.  
 In resource-limited settings, one factor to consider when monitoring centrally is the reliabil-
ity of the internet connection for uploading trial data. Depending on the method of data collec-
tion, and whether or not data are uploaded to a central database in real time, provision may 
need to be made for poor internet connections and/or occasional power outages.  
 
Central statistical monitoring 
Statistical algorithms can be developed to identify any unusual patterns of data within the trial 
database, and to review data at participant or site level. This can help determine systemic data 
rrors or the manufacture of falsified data. Examples of central statistical monitoring are: 
(a) looking for missing or invalid data: range checks to identify unexpected or abnormal values, 
e.g. extreme laboratory results or inverted blood pressure measurements.  
(b) discovering unusual data patterns: identifying data similarity (inliers), or data extremes (outli-
ers) within or between sites. These checks will highlight whether a site shows preference for cer-
tain values or digits, how they have rounded up or down values, or unusual frequency distribu-
tions (mean, variance, skewness).  
(c) Pharmacovigilance: signal surveillance of the adverse event data should also be reviewed to 
determine quickly whether there is an increase in frequency or type of particular events. 
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For trials where regular on-site visits are not possible, e.g. where sites are scattered across the 
globe, the use of statistical monitoring can help pinpoint areas on which to focus on-site monitor-
ing activities (Buyse et al 1999, Venet et al 2012; Kirkwood & Hackshaw 2011).  
 Minimizing errors from the beginning can also help to reduce the amount of on-site monitor-
ing visits required. Errors can be minimized by careful and detailed training for data collectors 
and through real-time centralized monitoring as described above. Regular training updates may 
also be useful. 
 
On-site monitoring 
On-site monitoring may consist of periodic site visits by a designated monitor (often the Trial 
Manager for noncommercial trials, or contracted independent monitors depending on the type of 
trial. Contracting local monitors may also be beneficial, as they will have relevant expertise in the 
local language, culture and practices). Early-phase trials, e.g. first in human studies, which carry 
an inherently higher risk, will usually take a 100% approach, ensuring that every data point is ac-
curate and verifiable against source data. For later-phase trials, or trials which incur less risk, a se-
lection of key data may be verified at site, for a certain percentage of participants. The visits can 
generally be divided into an initiation visit (prior to site opening and recruitment of the first pa-
tient), interim visits and a final close-out visit. Each visit is followed by production of a report.  
 
Risk-adapted monitoring  
Over the past decade there has been a significant rise in the number and complexity of clinical 
trials worldwide and, with this increase, a shift from traditional on-site monitoring to a more risk-
adapted approach. According to ICH-GCP ‘the extent and nature of clinical trial monitoring should 
be determined by aspects of the trial including objective, purpose, design, complexity, blinding, 
size and endpoints’. Risk-adapted approaches allow for a more targeted, flexible and less costly 
approach. The European Medicines Agency and the Food and Drug Administration recently pub-
lished papers on the merits of risk-based monitoring (EMA 2010, FDA 2013b), describing a more 
systematic approach that prioritizes monitoring procedures based on level of risk, setting priori-
ties based on these risks and identifying risk mitigation measures, thus reducing the cost and 
time associated with monitoring while ensuring patient safety and high-quality data collection.  
 
Risk assessment  
The type of monitoring considered for a trial (i.e. level of oversight, on-site, central and/or statis-
tical monitoring) should be proportionate to the level of risk of the study. The chief investiga-
tor/trial manager, or designate, should review the risks to the participant and sponsor, and to the 
study itself (e.g. in terms of data integrity), before submitting grant applications in order to fully 
reflect the needs of the trial. If the trial is high-risk, more frequent site visits may need to be con-
sidered, while low-risk trials may require only remote or central monitoring. Table 1 identifies the 
specific areas that should be considered in a risk assessment and in determining the extent and 
nature of monitoring required for a clinical trial (Box 1 for general examples). 
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Guidance for on-site monitoring 
Monitoring plans 
On completion of the risk assessment a monitoring plan should be devised. The monitoring plan 
is a living document that will be adapted as required over the course of the trial. The monitoring 
plan encompasses all the elements that relate to monitoring, comprising: 
 On-site and central monitoring activities; 
 Data monitoring and other oversight committees; 
 Supply and vendor oversight. 
Monitoring activities may change over the course of the study. For example, at the beginning fre-
quent monitoring should take place until the site and study management team are satisfied with 
progress. At this point visits may happen less often, or move to solely central and statistical-
based monitoring methods. Monitoring may also become more frequent if issues are identified at 
any stage. Rules for raising or lowering the rate of monitoring, or a change in the type of monitor-
ing, should be included in the monitoring plan. If independent monitors are contracted to under-
take this role in the trial, the agreement must contain some degree of flexibility so that the prin-
cipal investigator may amend the monitoring plan during the trial; this may be done through 
payment of monitoring days with the proviso that these may increase or decrease during the 
trial. 
 
Monitoring process 
The following section identifies the key areas of trial conduct that should be monitored during a 
site visit and identifies issues that may arise specifically in resource-poor settings. 
 
Source Documents / Data Quality Verification 
One of the key activities performed during an on-site monitoring visit is source data verification. 
This entails checking data from the database or case report form against data collected in source 
documents such as medical records, laboratory results, radiology films etc. The aim of source da-
ta verification is to ensure data accuracy and protecting the integrity of the final trial results. The 
monitor should query any discrepancies with the local site team and arrange for corrections of 
the database, as necessary. 
 Specific problems can arise during conducting source data verification in resource-poor set-
tings. Source documents (e.g. medical records) may not be available after patient discharge, or 
sufficient detail may not be captured in the records. In many countries patients purchase the 
medical record booklet and take it home with them at discharge. Full electronic patient manage-
ment systems may not exist in such settings.  
 The trial team should determine the site’s capacity to retain source documents for monitor-
ing before site initiation. If source documents are unavailable, or problems with retaining the da-
ta at a site are foreseeable, the trial team can create a pro forma source document including all 
case report form questions, in addition to other data required by the medical team to ensure ad-
equate care of the participant (this information should also be accessible to any clinical staff not 
involved in the trial who is caring for the patient). All data to be included in the case report form 
should then be transcribed from this source document. Where patients take home their medical 
records, it may be possible to photocopy or scan the records prior to discharge and to store them 
as a source document. The scanned copy of the record can be certified as a true copy of the rec-
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ord i.e. the scan and original copy should be reviewed for conformity and include a note to state 
that this is a true copy (EMA 2010, FDA 2003, FDA 2013a). 
 If source documents are adequately and appropriately maintained by the site staff, it is im-
portant that the medical record and other associated source documents are not shredded prem-
aturely. They must be available for the lifetime of the trial, and archived for a minimum of 5 years 
after its end (ICH GCP 1996). It is helpful to use stickers on the outside of the medical records 
(with permission from hospital administration) to flag to administrators the need for archiving. 
Further areas for consideration when conducting SDV are detailed in Table 2. 
 
Informed Consent  
Monitoring informed consent is a fundamental part of the conduct of a clinical trial and ensures 
that the rights of participants are respected. Monitoring of consent forms can be completed cen-
trally or on-site. If consent forms are monitored centrally, permission to transfer identifiable in-
formation to the trial team (possibly based outside the country) must first be obtained from the 
participant during the consenting process, with the inclusion of an appropriate clause in the con-
sent form. Monitoring of consent forms, however, is typically conducted as an on-site activity 
(Table 3).  
 
Pharmacy Monitoring 
Particular attention should be paid to the pharmacy during on-site monitoring visits. It is crucial 
to ensure that the investigational medicinal product is stored securely, under the correct condi-
tions for each specific product, with appropriate accountability logs in place (Table 4). 
 
Laboratory Monitoring 
There are a number of areas in the laboratory that should be checked during the monitoring visit. 
Points to consider are listed in Table 5. 
 
Adverse Events  
Monitoring adverse events is crucial for all trials as the safety of participants is of paramount im-
portance. Adverse events can be monitored centrally by means of signal surveillance, allowing 
the team to react quickly to any increase in the frequency of any side effects. Monitoring can also 
take place at site during review of the source documents to ensure that all adverse events are re-
ported to the trial team and ethics and regulatory authorities as required, and within the 
timeframes specified in the trial Standard Operating Procedure (Table 6). 
 
Other Documents 
Table 7 details a number of additional trial documents that should also be reviewed during the 
monitoring visit.  
 
Monitoring reports, corrective action, preventive action 
After the monitoring visit, the monitor should provide the site with a monitoring report that 
should be filed in the trial master file/investigator site file. The report will provide a review of ac-
tivities, progress, difficulties and issues of concern.  
 Sponsor have their own templates for the monitoring report, but these are typically in a tick-
box format to simplify the reporting as monitors may have several sites to review in a short time. 
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There will be space for comments, but these should always be a presentation of facts, without 
opinion.  
 The site should then develop a Corrective and Preventive Action plan to correct any issues 
identified. The site should undertake a root cause analysis to determine why something might 
have gone wrong, and to prevent the issue from recurring. The monitor will check the Corrective 
and Preventive Action plan for completeness and will follow up as required. 
 
Conclusion 
The value of effective monitoring for clinical trials should not be underestimated, and it should be 
incorporated at the very early stages of trial design. Conducting clinical trials in resource-poor 
settings can be challenging, but careful planning and effective, well conducted monitoring can as-
sist in ensuring reliable and accurate scientific results while adhering to local and international 
guidelines and maintaining patient safety throughout. 
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Table 1: Areas to consider when conducting a risk assessment to determine the extent and nature of monitoring required for a clinical trial 
 
Disease Area Short-acting illnesses  
e.g. pneumonia / flu 
 Short-acting illnesses will often have a shorter course of treatment, thus requiring a more intensive period of moni-
toring to capture the short treatment times.  
Long-lasting illnesses 
e.g. HIV 
 For trials with longer treatment periods, monitoring may be less frequent and less intense as there is more time to 
capture the information required and correct any errors. 
Design Complex versus simple  A complex design such as a double-blind randomised, placebo-controlled may require more intense monitoring due 
to the potential for more errors to occur. 
Randomisation and 
stratification 
 Complex randomisation systems have an increased risk of potential errors occurring and thus may require increased 
monitoring and verification to ensure procedures are conducted correctly. 
Sites Number and location  Increasing the number of sites will increase the complexity of the trial. 
 Both very fast and very slow recruitment may require more monitoring visits. For recruitment that is faster than ex-
pected errors may be more likely to occur if the trial team have a heavier workload. Conversely, if recruitment is 
slower than expected, monitoring may be required to encourage the team and identify issues that may be contribut-
ing to slow recruitment rates. 
Experience  The education, training and experience of the investigator team also play a role in determining monitoring require-
ments. If the teams lack experience, more intense monitoring may be required.  
Resources  The resources and facilities available at the site may also determine the level of monitoring required as there may be 
few resources and little space accessible to staff at the site and this could hinder the efficient conduct of the trial. 
Study popula-
tion 
Vulnerable groups Monitoring may need to be intensified where: 
 Vulnerable groups are enrolled, e.g. children or pregnant women, and the risk of adverse effects may be higher. 
 Healthy volunteers are enrolled with a risk of a healthy individual becoming unwell. 
 Capacity to consent is impaired, i.e. participants are unconscious or suffering a traumatic brain injury. 
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 Participants are illiterate. Additional safeguards may be needed to ensure participant rights are respected. 
Investigation-
al Medicinal 
Product (IMP): 
Licensed  If side effects are not well known, AE reporting and review may need to be intensified. 
 Alternatively, if side effects are well-known, but the drug will be used in a new population, more frequent reporting 
may be warranted.  
Unlicensed  Is a new drug is used, or an old drug is used outside its marketing authorisation, more intense monitoring may be re-
quired. For first in man studies, monitoring is conducted in close to real time. When a participant is dosed and data 
are collected, the monitor may check these data against the source document. 
 Data that will be used in licensing applications will normally require a larger number of on-site visits. 
Type of IMP  Need to consider whether the IMP requires refrigeration and cold chain transport. The method for maintaining cold 
chain and IMP integrity need to be monitored closely. 
 If placebo is administered details of manufacture will need to be documented and procedures for identifying the 
product, if the study is blinded, put in place. 
Data Man-
agement sys-
tems 
Electronic  Increasingly trials are using electronic data management systems to collect, collate and analyse data. Databases are 
likely to differ in terms of their testing and validation procedures and this will influence the level of monitoring re-
quired.  
 Electronic database systems usually require a good internet connection. This may raise issues where the internet 
connectivity is poor, delaying the submission of data and possibly reporting of AEs, rendering the process high-risk 
with more monitoring requirements. 
Paper Case Report 
Forms 
 Important to check how data will be entered into the database (e.g. with double data entry or other checks in place). 
Procedures for transferring data must be documented and may have an impact on the level of associated risk and 
thus the level of monitoring required. 
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Confidentiality  There is increasing awareness of breaches in confidentiality, which might take place with the transfer of identifiable 
data across boundaries. The risk associated with confidentiality should be assessed and the level of monitoring de-
tailed accordingly. 
Oversight 
mechanisms 
TSC, DMC/DSMB, Trial 
Management Group  
 These committees provide an additional means of monitoring the trial data and may help to reduce some risks asso-
ciated with trial conduct. 
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Table 2. Areas to consider when undertaking SDV 
 
What is the source document?  Determine this prior to site initiation 
 Create source files if required 
 Take certified copies of any records that go home with the patient 
Variability of access to source  Conduct risk assessment as part of site initiation to determine asso-
ciated risks 
Variability of quality of source 
document 
 Ensure site understands the importance of source documents 
 Help site to annotate medical records appropriately and create 
study proforma notes, if required 
Discrepancies and query resolu-
tion 
 Monitoring plan (or Data Management Standard Operating Proce-
dures) to detail how queries will be resolved, including changes to 
the database 
 Site principal investigator to sign off all changes to case report forms 
after the monitoring visit (if specified in the Data Management Op-
erating Procedures). 
 Data to be entered into database in a timely fashion to permit in-
terim analyses on maximum number of data points. 
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Table 3. Areas to consider when monitoring informed consent 
 
The participant information 
sheet and consent form 
 Ensure the current ethically approved version is in use. 
 Ensure translation and back-translation has been performed, with appro-
priate documentation. 
 Specific consent should be obtained for genetic analyses and retention of 
samples. 
 The documents should be written in line with cultural beliefs of the 
community (local ethics committees will help ensure the consenting 
documents are appropriate).  
Provision of consent  The monitor should check if only the individual themselves can provide 
consent for inclusion in the study or if the protocol allows others to also 
provide consent on the individual’s behalf – e.g. head of household, 
community leader, guardian etc. 
 Emergency trial – use of legal representatives to provide consent. 
 Community assent, e.g. as part of the sensitization process in approach-
ing a community to take part in the trial. 
 Ensure age of consent is documented and checked and that guardi-
ans/parents have counter-signed as required. 
Impartial witness If impartial witnesses are involved (e.g. for illiterate patients): 
 Ensure the impartial witness is not on the trial delegation log. 
 Ensure the participant thumbprints the consent form, and witness signs 
attesting that the participant is happy to take part in the study. 
Completion of the consent 
form 
 Check all elements of the consent form  
o Participant study number added to form 
o Appropriate person has signed 
o Appropriate person has taken consent (trained and included on 
delegation log) 
o Dated on same day as enrolled 
o Most up-to-date version in use 
 Ensure that consent forms are filed for all participants. 
 Ensure that participants are eligible. 
 Ensure that the participant had capacity to consent, e.g. if abnormal 
mental status reported, was the participant capable of understanding the 
information provided? This is particularly important in emergency trials. 
Data protection  Ensure that there is a clause in the consent form for allowing monitors to 
review identifiable data, e.g. source documents. 
 If identifiable data will be transferred outside the country, this must be 
included on the PIS and consent form. 
Waivers of consent  Usually only in emergency trials. 
 Must be agreed by the relevant ethics committees. 
 Consent from participant to be obtained as soon as possible once they 
recover capacity. 
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Table 4. Areas to consider when monitoring the pharmacy 
 
Pharmacy  Points to consider  
Documentation/ 
Delegation log 
 Ensure a pharmacy file is in place with all relevant SOPs and logs relating to the 
IMP. Pharmacy personnel working on the trial must be included on the delega-
tion log and have evidence of appropriate training on GCP and trial-specific 
procedures relating to the pharmacy. 
Protocol compli-
ance/SOPs/ Local 
regulations 
 Ensure that pharmacy procedures comply with the trial protocol, pharmacy 
specific standard operating procedures and local regulations.  
 Many regulatory authorities (though not all) will have guidelines for local re-
quirements for conducting clinical trials and these should be strictly adhered 
to.  
 Compliance with Pharmacy Investigator Brochure should be checked and 
Summary of Product Characteristics and the Certificate of Analyses examined. 
Investigational 
medicinal product 
Storage 
 Temperature monitoring logs should be complete and within range where re-
quired for specific investigational medicinal products. 
 Access to the investigational medicinal product should be secure and back-up 
facilities available in case of issues with electricity supply.  
 Procedures for dealing with such issues should be documented and understood 
by the pharmacist.  
Labeling  Investigational medicinal products should be appropriately labelled in the 
pharmacy and on dispensing to the study team/patient.  
Expiry dates  All expiry dates should be in range and noted on the accountability logs. 
Randomisation  Procedures for randomization should be clear and prescriptions/dispensing 
conducted according to the correct randomization assignment.  
Accountability  Accountability logs should be in place for receiving shipments and dispensing 
investigational medicinal products and should balance with a physical stock 
check.  
Breaking blind  Understanding should be checked and procedures clearly described in standard 
operating procedures.  
Shipment  Chain of custody and information on temperature stability during shipment (if 
required) should be documented. 
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Table 5 Areas to consider when monitoring the laboratory 
 
Laboratory Points to consider  
Documentation  Protocol and laboratory specific standard operating procedures for sample col-
lection, analysis, storage, shipment and disposal should be reviewed. 
 Lab personnel working on the trial must be included on the delegation log and 
have evidence of appropriate training on Good Clinical Practice and trial-
specific procedures relating to laboratory procedures.  
Agreements and 
ontracts 
 Material Transfer Agreements should be in place if samples are to be shipped 
outside the country for analysis.  
Logistics  Traceability of tissue samples: the monitor should follow the journey of a sam-
ple from the documentation, from clinic to lab to dissemination of results, 
storage and shipment, if applicable.  
 Details relating to sample tracking, processes for dealing with issues and identi-
fication of any samples that should not to be stored (e.g. if consent not given) 
should all be documented and checked. 
 Procedure for reporting / logging results(e.g. LIMS system used in some coun-
tries) should also be checked to ensure that critical values and adverse events 
are fed back to the clinical team as soon as possible 
Facilities/ Equip-
ment/supply 
 Check the Quality Control process for machines (e.g. incubators, hoods etc), 
ensure back-up generators are in place for sample storage (or process for elec-
tricity losses in place) and that adequate supply of reagents, kits, storage tubes 
etc are in place. 
 Review references ranges and lab accreditation certificates. 
Sample storage  Check temperature of freezers (e.g. -80 oC freezers) and duration of storage. 
Identify any freeze-thaw problems and how this is handled, if appropriate. 
 Labels on samples should be reviewed to ensure that there are no patient iden-
tifiers, that they comply with standard operating procedure requirements, and 
that there is no label deterioration. 
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Table 6. Areas to consider when monitoring adverse events 
 
Reporting to the chief 
investigatorand the coordi-
nating centre/trial team 
 Ensure protocol contains detailed adverse event reporting require-
ments, particularly serious adverse events and suspected unexpected 
serious adverse events. A separate standard oprating procedure for ad-
verse events monitoring and reporting may be in place and this should 
also be checked. 
Difference in concomitant 
medication terminology 
 Monitor should have local knowledge of terminology used if different 
to the protocol. 
Adverse events in source 
documentation  
 Ensure that the adverse event is adequately described in the on-site 
medical notes, as well as in the CRF. 
 Check the medical record also for any adverse event that had not been 
submitted to the trial team.  
Reporting to ethics and 
regulatory authorities 
 Many regulatory authorities, ethics committees and sponsors have dif-
fering timelines for reporting. All timelines for reporting should be de-
tailed in a Standard Operating Procedure (SOP). 
 Review reporting timelines during monitoring visit. 
 
 
 
Table 7. Areas to consider for monitoring remaining trial documents  
 
Training log  Ensures that all site staff have the appropriate training, education and 
experience to undertake their roles in the study 
 To be used in conjunction with delegation logs 
Delegation logs  Ensure that staff who undertake specific roles have been delegated 
these correctly and details are included on the log, e.g. for staff taking 
consent they must have been trained accordingly and delegated the 
task as detailed on the log. 
Screening logs  Helps to determine issues surrounding enrolment; e.g. can demon-
strate where small changes to the eligibility criteria, which will not af-
fect the overall trial, may increase recruitment. 
Randomisation log  Can be compared against drug accountability logs to ensure that the 
appropriate investigational medicinal product (randomisation arm) is 
given to the correct participant. 
Ethics and regulatory  Ensure that all appropriate approvals are in place. 
 Ensure that any conditions applicable to the trial have been met. 
 Ensure that all amendments have been submitted to all parties. 
Contracts and agreements  Check conditions and instructions noted in contracts. 
 Check compliance with terms and conditions, particularly restrictions 
with Material Transfer Agreements and Data Transfer Agreements. 
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Box 1 
A phase III placebo-controlled trial of a licensed drug, but used outside of its standard indication, at a dose 
higher than what would normally be given.  
 
Although the drug is licensed, and there should be good data on expected adverse events, in this instance 
the drug is being used outside its licensed indication and at a higher dose. Therefore, there might be a 
higher frequency of adverse events, or the adverse events may be more severe. It would be advisable to 
undertake adaptive monitoring in this situation, with more frequent on-site monitoring at the beginning 
of the trial. When the rate and severity of events are known, monitoring intensity can slowly decrease. 
 
A phase II dose-escalation trial of a new unlicensed drug to be used for the treatment of pneumonia 
Earlier-phase trials tend to be higher-risk and will thus require close monitoring throughout the trial. 
Dose-escalation trials, in particular, need to be monitored in real-time (i.e. as participants are registered 
and receive their dose, the monitor should be reviewing their data) as it is crucial that the data are verified 
as accurate before moving to the next dosing level. 
 
A phase III RCT comparing efficacy of two statins, both used within their licensed indication. The trials team 
use central statistical monitoring. 
Here the risk profile of the investigational product is known, and the side effects are minimal. In addition, 
the trial management team is monitoring data in real time. In this instance, regular on-site monitoring 
would not be required unless the statistical monitoring highlights an issue at a site, triggering a monitoring 
visit. This may include: missing outcome data, increased frequency of adverse events, or increased ad-
verse event severity.  
 
